BeyondSpring (BYSI) Current Deferred Revenue (2020 - 2024)
BeyondSpring (BYSI) posted Current Deferred Revenue of $2.0 million for Q2 2024, up 14.28% sequentially from $1.8 million in Q4 2023, and up 14.28% YoY from $1.8 million in Q3 2023.
BeyondSpring (BYSI) Current Deferred Revenue (2020 - 2024) Analysis & Trends
BeyondSpring has reported Current Deferred Revenue for 5 years, with the latest figure at $2.0 million in Q2 2024.
- Quarterly Current Deferred Revenue rose 14.28% year-over-year to $2.0 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $2.0 million (up 14.28% YoY) and the FY2023 annual result came in at $1.8 million, up 29.61% from the prior year.
- Current Deferred Revenue advanced to $2.0 million in Q2 2024 per BYSI's latest filing, from $1.8 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $2.0 million in Q2 2024 and troughed at $1.3 million in Q4 2020.
- A 5-year average of $1.5 million and a median of $1.4 million in 2021 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2022 and 2023: Current Deferred Revenue dropped 1.31% in 2022, then climbed 29.61% in 2023.
- Over 5 years, Current Deferred Revenue stood at $1.3 million in 2020, then gained by 1.41% to $1.4 million in 2021, then slipped by 1.31% to $1.4 million in 2022, then rose by 29.61% to $1.8 million in 2023, then gained by 14.28% to $2.0 million in 2024.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $2.0 million, $1.8 million, and $1.8 million for Q2 2024, Q4 2023, and Q2 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.97 Bn | 132.12 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.64 Bn | 78.64 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.55 Bn | 60.37 Bn | 1.37 Bn |
| 4 | Moderna | 61.26 Bn | 56.12 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.30 Bn | 37.20 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.66 Bn | 28.35 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.68 Bn | 10.29 Bn | 668.28 Mn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - |
| 10 | BeyondSpring | 30.20 Mn | 30.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 2.00 Mn |
| Dec 31, 2023 | 1.75 Mn |
| Jun 30, 2023 | 1.75 Mn |
| Dec 31, 2022 | 1.35 Mn |
| Jun 30, 2022 | 1.35 Mn |
| Dec 31, 2021 | 1.37 Mn |
| Sep 30, 2021 | 1.53 Mn |
| Jun 30, 2021 | 1.35 Mn |
| Mar 31, 2021 | 1.35 Mn |
| Dec 31, 2020 | 1.35 Mn |